Rationally Designed Monodisperse Gd2 O3 /Bi2 S3 Hybrid Nanodots for Efficient Cancer Theranostics.
Sign Up to like & getrecommendations! Published in 2018 at "Small"
DOI: 10.1002/smll.201802904
Abstract: Multifunctional nanotheranostic agents are of particular importance in the field of precise nanomedicine. However, a critical challenge remains in the rational fabrication of monodisperse multicomponent nanoparticles with enhanced multifunctional characteristics for efficient cancer theranostics. Here,… read more here.
Keywords: gd2; hybrid nanodots; monodisperse gd2; efficient cancer ... See more keywords
Easy synthesis of N-doped graphene by milling exfoliation with electrocatalytic activity towards the Oxygen Reduction Reaction (ORR)
Sign Up to like & getrecommendations! Published in 2017 at "International Journal of Hydrogen Energy"
DOI: 10.1016/j.ijhydene.2017.08.084
Abstract: Abstract We report a novel process to synthesize graphene (G) catalyst by mechanical milling using graphite flakes as the precursor. G sample has been doped ex situ with hydrazine as nitrogen source via solvothermal procedure… read more here.
Keywords: nitrogen; gd2; synthesis doped; doped graphene ... See more keywords
Intravenous and intracranial GD2-CAR T cells for H3K27M+ diffuse midline gliomas
Sign Up to like & getrecommendations! Published in 2024 at "Nature"
DOI: 10.1038/s41586-024-08171-9
Abstract: H3K27M-mutant diffuse midline gliomas (DMGs) express high levels of the disialoganglioside GD2 (ref. 1). Chimeric antigen receptor-modified T cells targeting GD2 (GD2-CART) eradicated DMGs in preclinical models1. Arm A of Phase I trial no. NCT04196413 (ref. 2) administered… read more here.
Keywords: gd2 cart; gd2; diffuse midline; midline gliomas ... See more keywords
Manipulating clusters by regulating N,O chelating ligands: structures and multistep assembly mechanisms
Sign Up to like & getrecommendations! Published in 2020 at "CrystEngComm"
DOI: 10.1039/c9ce01730e
Abstract: We obtained a binuclear Gd(III) complex [Gd2(L1)2(NO3)4] (1, HL1 = (E)-2-(2-(pyridin-2-ylmethyleneamino)ethoxy)ethanol) by reacting N2O2-tetradentate chelating ligand HL1 with Gd(NO3)3·6H2O at solvothermal temperature of 100 °C. Time-dependent high-resolution electrospray ionization mass spectrometry (HRESI-MS) followed the formation… read more here.
Keywords: gd2; chelating ligands; manipulating clusters; clusters regulating ... See more keywords
IGF2BP1 fosters an immunosuppressive tumor microenvironment in high-risk neuroblastoma, contributing to their resistance to immunotherapy
Sign Up to like & getrecommendations! Published in 2025 at "Oncoimmunology"
DOI: 10.1080/2162402x.2025.2584408
Abstract: ABSTRACT The incorporation of the current immunotherapy, GD2-targeting monoclonal antibodies, into the standard of care has moderately improved clinical outcomes in children with high-risk neuroblastoma (HR-NB); however, overall survival remains low. More than 50% of… read more here.
Keywords: tumor microenvironment; immunotherapy; high risk; igf2bp1 ... See more keywords
EXTH-129. Evaluating GD2-targeting antibody-drug conjugates for DIPG using human organoid-based preclinical platforms
Sign Up to like & getrecommendations! Published in 2025 at "Neuro-Oncology"
DOI: 10.1093/neuonc/noaf201.1462
Abstract: Diffuse intrinsic pontine glioma (DIPG) is a universally fatal pediatric brain tumor with no approved targeted therapies and a median survival of less than 12 months. The frequent presence of H3K27M mutations in DIPG is… read more here.
Keywords: culture; drug conjugates; antibody drug; dipg ... See more keywords
First-line Anti-GD2 Therapy Combined With Consolidation Chemotherapy in 3 Patients With Newly Diagnosed Metastatic Ewing Sarcoma or Ewing-like Sarcoma
Sign Up to like & getrecommendations! Published in 2022 at "Journal of Pediatric Hematology/Oncology"
DOI: 10.1097/mph.0000000000002488
Abstract: Despite multimodal therapy, the prognosis of patients with metastatic Ewing sarcoma (ES) remains poor, with new treatments urgently needed. The disialoganglioside GD2, a well-established tumor-associated antigen, is expressed in 40% to 90% of ES cells,… read more here.
Keywords: sarcoma; gd2; like sarcoma; metastatic ewing ... See more keywords
Ganglioside GD2 Contributes to a Stem‐Like Phenotype in Intrahepatic Cholangiocarcinoma
Sign Up to like & getrecommendations! Published in 2024 at "Liver International"
DOI: 10.1111/liv.16208
Abstract: GD2, a member of the ganglioside (GS) family (sialic acid‐containing glycosphingolipids), is a potential biomarker of cancer stem cells (CSC) in several tumours. However, the possible role of GD2 and its biosynthetic enzyme, GD3 synthase… read more here.
Keywords: contributes stem; gd2 contributes; intrahepatic cholangiocarcinoma; ganglioside gd2 ... See more keywords
Anti-GD2 IgA kills tumors by neutrophils without antibody-associated pain in the preclinical treatment of high-risk neuroblastoma
Sign Up to like & getrecommendations! Published in 2021 at "Journal for Immunotherapy of Cancer"
DOI: 10.1136/jitc-2021-003163
Abstract: Background The addition of monoclonal antibody therapy against GD2 to the treatment of high-risk neuroblastoma led to improved responses in patients. Nevertheless, administration of GD2 antibodies against neuroblastoma is associated with therapy-limiting neuropathic pain. This… read more here.
Keywords: gd2; high risk; antibody; risk neuroblastoma ... See more keywords
Targeting disialoganglioside GD2 with chimeric antigen receptor-redirected T cells in lung cancer
Sign Up to like & getrecommendations! Published in 2022 at "Journal for Immunotherapy of Cancer"
DOI: 10.1136/jitc-2021-003897
Abstract: Background We explored whether the disialoganglioside GD2 (GD2) is expressed in small cell lung cancer (SCLC) and non-SCLC (NSCLC) and can be targeted by GD2-specific chimeric antigen receptor (CAR) T cells. Methods GD2 expression was… read more here.
Keywords: car; gd2; cell; lung cancer ... See more keywords
Therapeutic efficacy of antibody-drug conjugates targeting GD2-positive tumors
Sign Up to like & getrecommendations! Published in 2022 at "Journal for Immunotherapy of Cancer"
DOI: 10.1136/jitc-2022-004646
Abstract: Background Both ganglioside GD2-targeted immunotherapy and antibody-drug conjugates (ADCs) have demonstrated clinical success as solid tumor therapies in recent years, yet no research has been carried out to develop anti-GD2 ADCs against solid tumors. This… read more here.
Keywords: gd2; drug conjugates; adcs; antibody drug ... See more keywords